Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Haemonetics (HAE) Non-Current Assets (2016 - 2025)

Haemonetics has reported Non-Current Assets over the past 16 years, most recently at $1.5 billion for Q4 2025.

  • Quarterly results put Non-Current Assets at $1.5 billion for Q4 2025, up 1.43% from a year ago — trailing twelve months through Dec 2025 was $6.2 billion (up 1.16% YoY), and the annual figure for FY2025 was $1.5 billion, up 6.26%.
  • Non-Current Assets for Q4 2025 was $1.5 billion at Haemonetics, roughly flat from $1.5 billion in the prior quarter.
  • Over the last five years, Non-Current Assets for HAE hit a ceiling of $1.6 billion in Q3 2024 and a floor of $1.1 billion in Q1 2022.
  • Median Non-Current Assets over the past 5 years was $1.2 billion (2022), compared with a mean of $1.3 billion.
  • Biggest five-year swings in Non-Current Assets: soared 69.77% in 2021 and later decreased 2.01% in 2022.
  • Haemonetics' Non-Current Assets stood at $1.1 billion in 2021, then grew by 6.31% to $1.2 billion in 2022, then rose by 22.5% to $1.4 billion in 2023, then rose by 6.27% to $1.5 billion in 2024, then rose by 1.43% to $1.5 billion in 2025.
  • The last three reported values for Non-Current Assets were $1.5 billion (Q4 2025), $1.5 billion (Q3 2025), and $1.5 billion (Q2 2025) per Business Quant data.